Want to see GB:AZN full AI Analyst Report?
Top Page
AstraZeneca
(LSE:AZN)
Select Model
Select Model
Rating:66Neutral
Price Target:
12,485.00 p
▲(0.07% Upside)
Action:Reiterated
Date:07/28/26
The score is driven primarily by strong underlying financial profitability and a constructive earnings outlook with reiterated guidance and robust pipeline momentum. These positives are tempered by weak technical trend signals (price below major moving averages), mixed cash conversion with higher net debt in H1, and valuation that looks more growth-priced than discounted.
Positive Factors
Oncology Growth and Market Position
Strong oncology growth across several major brands reinforces AstraZeneca’s leadership in a high-value therapeutic area. Broad product momentum can support durable revenue expansion and help offset maturity or exclusivity pressure elsewhere.
Negative Factors
Loss of Exclusivity Pressure
Generic entry, pricing pressure and loss of exclusivity can structurally erode sales from established medicines. This creates recurring portfolio-replacement needs and may moderate company-wide growth as mature products decline.
Read all positive and negative factors
Positive Factors
Negative Factors
Oncology Growth and Market Position
Strong oncology growth across several major brands reinforces AstraZeneca’s leadership in a high-value therapeutic area. Broad product momentum can support durable revenue expansion and help offset maturity or exclusivity pressure elsewhere.
Read all positive factors
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£186.76B
Dividend Yield2.01%
Average Volume (3M)3.81M
Price to Earnings (P/E)24.0
Beta (1Y)1.20
Revenue Growth4.71%
EPS Growth21.16%
CountryUK
Employees96,100
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)6.71
Shares Outstanding1,551,043,500
10 Day Avg. Volume2,433,007
30 Day Avg. Volume3,806,371
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.91
Price to Sales (P/S)4.90
P/FCF Ratio33.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£16,093.23Price Target Upside28.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)10.24
Revenue Forecast (FY)£63.36B
AstraZeneca Business Overview & Revenue Model
Company Description
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, ke...
How the Company Makes Money
AstraZeneca primarily makes money by selling patented, branded prescription medicines. Revenue is largely generated from product sales across its major therapy-area portfolios (notably Oncology, CVRM, and Respiratory & Immunology), where sales vol...
AstraZeneca Earnings Call Summary
Earnings Call Date:Jul 27, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 30, 2026
Earnings Call Sentiment Positive
The call presented strong commercial momentum (H1 revenue +6%, oncology +15%, double-digit growth in several franchises), meaningful pipeline progress (multiple positive Phase III readouts, 25 upcoming pivotal readouts, new NMEs and approvals), and clear launch investments. These positives were offset by several notable setbacks — a failed CARDIO-TTRansform primary endpoint, some Phase III misses (Ultomiris HSCT‑TMA), loss‑of‑exclusivity impacts (Farxiga and others) that depressed biopharma revenues, and near‑term cash/working-capital impacts leading to higher net debt. Management reiterated guidance and emphasized long‑term confidence (2030 ambition) and significant late‑stage optionality. On balance the advances, approvals and pipeline scale materially outweigh the setbacks reported on the call.Positive Updates
Top-line and EPS Growth
Total revenue increased 6% in H1 2026 (11% excl. Farxiga & Brilinta) and core EPS rose 11% in H1, with the company reiterating full-year guidance of mid- to high-single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates.
Negative Updates
CARDIO-TTRansform (Wainua) Failed Primary Endpoint
CARDIO-TTRansform did not meet its primary endpoint: adding Wainua to contemporary standard of care did not produce a statistically significant benefit on the composite of CV mortality and recurrent CV events, representing a major pipeline disappointment and a reminder of clinical risk.
Read all updates
Q2-2026 Updates
Positive
Negative
Top-line and EPS Growth
Total revenue increased 6% in H1 2026 (11% excl. Farxiga & Brilinta) and core EPS rose 11% in H1, with the company reiterating full-year guidance of mid- to high-single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates.
Read all positive updates
Company Guidance
AstraZeneca reiterated its 2026 outlook, guiding full‑year total revenue to grow by a mid‑ to high single‑digit percentage and core EPS to rise by a low double‑digit percentage at constant exchange rates (CER). In H1 2026 the company reported total revenue +6% (and +11% excluding Farxiga and Brilinta), product revenue +6%, alliance revenue +29% and core EPS +11%; core gross margin was 83% in H1 (expected to be lower in H2 seasonally but stable-to-slightly-higher versus 2025 for the full year). Core R&D expense rose 6% and represented 23% of revenue in H1, with R&D expected at the upper end of the low‑20s percent range for 2026; core SG&A also increased 6%. Other H1 metrics: CapEx $1.5bn (CapEx expected to increase by ~1/3 in 2026), deal‑related payments $3.3bn in H1 including a $1.2bn upfront for CSPC, expected milestone payments of ~ $2.5bn for the full year, new BD upfronts YTD just over $2bn, other operating income $341m in H1 (anticipated to be broadly similar in H2), net debt up ≈$3.5bn in H1, and core finance costs expected to be higher in H2 following refinancing.AstraZeneca Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
74
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.27B | 58.74B | 52.94B | 46.58B | 44.25B | 37.11B |
| Gross Profit | 48.57B | 48.11B | 39.70B | 34.45B | 28.04B | 22.60B |
| EBITDA | 20.45B | 19.83B | 14.86B | 13.20B | 8.63B | 4.59B |
| Net Income | 10.43B | 10.22B | 6.89B | 6.06B | 3.28B | 109.85M |
Balance Sheet | ||||||
| Total Assets | 116.43B | 114.07B | 104.03B | 101.12B | 96.48B | 105.36B |
| Cash, Cash Equivalents and Short-Term Investments | 4.99B | 5.74B | 5.65B | 5.91B | 6.24B | 6.37B |
| Total Debt | 32.41B | 29.62B | 30.11B | 28.41B | 29.14B | 30.69B |
| Total Liabilities | 65.80B | 65.36B | 63.16B | 61.95B | 59.42B | 66.08B |
| Stockholders Equity | 50.56B | 48.67B | 40.79B | 39.14B | 37.04B | 39.27B |
Cash Flow | ||||||
| Free Cash Flow | 8.43B | 8.67B | 7.28B | 6.57B | 7.24B | 3.76B |
| Operating Cash Flow | 13.74B | 14.57B | 11.86B | 10.35B | 9.81B | 5.96B |
| Investing Cash Flow | -8.19B | -6.81B | -7.98B | -4.06B | -2.96B | -11.06B |
| Financing Cash Flow | -7.66B | -7.54B | -4.00B | -6.57B | -6.82B | 3.65B |
AstraZeneca Technical Analysis
Negative
12476.00
Price Trends
12431.08
Negative
13045.57
Negative
13560.62
Negative
Market Momentum
-120.12
Negative
39.31
Neutral
27.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AZN, the sentiment is Negative. The current price of 12476 is above the 20-day moving average (MA) of 11958.80, above the 50-day MA of 12431.08, and below the 200-day MA of 13560.62, indicating a bearish trend. The MACD of -120.12 indicates Negative momentum. The RSI at 39.31 is Neutral, neither overbought nor oversold. The STOCH value of 27.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AZN.
AstraZeneca Risk Analysis
AstraZeneca disclosed 19 risk factors in its most recent earnings report. AstraZeneca reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment Q4, 2024
AstraZeneca Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £4.39B | 47.30 | 8.40% | 2.52% | 1.94% | -43.71% | |
73 Outperform | £73.63B | 14.97 | 28.35% | 3.79% | 4.97% | 42.62% | |
70 Outperform | £3.31B | 12.08 | 15.05% | 3.97% | 2.48% | 3.36% | |
68 Neutral | £8.91B | 18.29 | 12.25% | 2.83% | 2.17% | 27.33% | |
66 Neutral | £186.76B | 23.97 | 21.68% | 2.01% | 4.71% | 21.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GB:AZN
AstraZeneca
11,650.00
-63.85
-0.55%
GB:CTEC
ConvaTec
221.00
-9.50
-4.12%
GB:GSK
GlaxoSmithKline
1,803.50
366.64
25.52%
GB:HIK
Hikma Pharmaceuticals
1,535.00
-54.84
-3.45%
GB:SN
Smith & Nephew
1,025.50
-354.84
-25.71%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
62.50
18.07
40.68%
AstraZeneca Corporate Events
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Enhertu tops standard care in first-line HER2-mutant lung cancer trial
Positive
Aug 17, 2026
AstraZeneca and Daiichi Sankyo reported that their HER2-directed antibody-drug conjugate Enhertu significantly improved progression-free survival compared with the current global standard of care in a Phase III trial of first-line treatment for pa...
Business Operations and Strategy
AstraZeneca Halts Key Lung Cancer Trial of Volrustomig After Missed Efficacy Goals
Negative
Aug 17, 2026
AstraZeneca has halted its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy as a first-line treatment for metastatic non-small cell lung cancer patients whose tumours express PD-L1 below 50%, after an independent data monitor...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Tagrisso–Orpathys Combo Delivers Phase III Survival Gains in MET-Driven Lung Cancer
Positive
Aug 17, 2026
AstraZeneca reported positive Phase III results from the global SAFFRON trial, showing that Tagrisso combined with Orpathys significantly improved progression-free and overall survival versus platinum-based chemotherapy in MET-driven EGFR-mutated ...
Business Operations and StrategyDelistings and Listing Changes
AstraZeneca Adds Employee Scheme Shares to London Listing
Neutral
Aug 3, 2026
AstraZeneca PLC has admitted 8,855 additional ordinary shares of $0.25 each to trading on the Main Market of the London Stock Exchange, bringing the total number of securities in issue to 1,551,033,389. These new shares are fully fungible with exi...
Regulatory Filings and Compliance
AstraZeneca Updates Market on Total Voting Rights
Neutral
Aug 3, 2026
AstraZeneca has reported that, as of 31 July 2026, its issued share capital with voting rights comprises 1,551,033,389 ordinary shares, with no shares held in treasury, resulting in an equal number of total voting rights. This updated voting right...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca Wins EU Nod for Datroway, Strengthening TNBC Oncology Portfolio
Positive
Jul 31, 2026
AstraZeneca and Daiichi Sankyo have secured European Union approval for Datroway as the only TROP2-directed medicine with a demonstrated overall survival benefit in first-line treatment of unresectable or metastatic triple-negative breast cancer p...
Business Operations and StrategyRegulatory Filings and Compliance
AstraZeneca’s Alexion Reports Mixed Ultomiris Trial Results in HSCT‑TMA, Advances Paediatric Filings
Neutral
Jul 27, 2026
AstraZeneca’s rare disease unit Alexion reported mixed Phase III results for Ultomiris in thrombotic microangiopathy after haematopoietic stem cell transplant, highlighting divergent outcomes between adult and paediatric populations. In adul...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Sone-Ve delivers pivotal survival benefit in CLDN18.2-positive gastric cancer
Positive
Jul 27, 2026
AstraZeneca reported positive Phase III results for its wholly owned antibody drug conjugate sonesitatug vedotin (Sone-Ve) in the CLARITY-Gastric01 trial, showing a statistically significant and clinically meaningful overall survival benefit in se...
Business Operations and StrategyDividendsFinancial Disclosures
AstraZeneca Delivers Solid H1 Growth and Bolsters Pipeline with Strategic Deals
Positive
Jul 27, 2026
AstraZeneca reported H1 2026 total revenue of $30.7 billion, up 6% at constant exchange rates, driven by strong oncology and rare disease sales despite headwinds from U.S. Farxiga loss of exclusivity and Chinese pricing reforms. Core operating pro...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca Wins EU Nod for Etcamah Combo in First-Line Advanced Breast Cancer
Positive
Jul 23, 2026
AstraZeneca has secured European Union approval for Etcamah (camizestrant), a next-generation oral SERD and complete estrogen receptor antagonist, in combination with CDK4/6 inhibitors as a first-line treatment for ER-positive, HER2-negative advan...
Business Operations and StrategyM&A Transactions
AstraZeneca Buys Global Rights to Dizal’s Zegfrovy in $1.5bn Lung Cancer Deal
Positive
Jul 14, 2026
AstraZeneca has signed an exclusive global licence deal with China’s Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for non-small cell lung cancer with exon 20 insertion mutations, securing worldw...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Wainua misses primary goal in major ATTR-CM heart trial
Negative
Jul 9, 2026
AstraZeneca and Ionis reported that the Phase III CARDIO-TTRansform trial of Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy failed to meet its primary endpoint, showing no statistically significant reduction in c...
Business Operations and StrategyRegulatory Filings and Compliance
AstraZeneca Adds 14,784 Shares Under Employee Schemes on LSE Main Market
Neutral
Jul 1, 2026
AstraZeneca has admitted 14,784 additional ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market, bringing its total shares in issue to 1,551,024,534. The new shares, fully fungible with existing stock, were iss...
Regulatory Filings and Compliance
AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
Neutral
Jul 1, 2026
AstraZeneca reported that, as of 30 June 2026, its issued share capital with voting rights stands at 1,551,024,534 ordinary shares, each with a nominal value of US$0.25, and that no shares are held in Treasury. This figure, which represents the co...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
AstraZeneca and Daiichi Sankyo win EU tumour‑agnostic approval for Enhertu
Positive
Jun 29, 2026
AstraZeneca and Daiichi Sankyo have secured European Commission approval for Enhertu as the first tumour-agnostic HER2-directed therapy and antibody drug conjugate for adults with previously treated, unresectable or metastatic HER2-positive solid ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
AstraZeneca’s Datroway Wins EU Backing for First-Line Triple-Negative Breast Cancer
Positive
Jun 29, 2026
AstraZeneca and Daiichi Sankyo’s Datroway has been recommended for approval in the European Union as a first-line monotherapy for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhi...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
AstraZeneca Wins First Targeted U.S. Approval for PTEN-Deficient Metastatic Prostate Cancer
Positive
Jun 15, 2026
AstraZeneca has secured U.S. approval for its AKT inhibitor Truqap (capivasertib) in combination with abiraterone and prednisone as the first targeted therapy for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prosta...
Business Operations and StrategyDelistings and Listing Changes
AstraZeneca Adds Employee Scheme Shares to London Listing
Neutral
Jun 1, 2026
AstraZeneca has admitted 14,120 additional ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market, bringing the total number of shares in issue to 1,551,009,750. The new shares are fully fungible with existing or...
Regulatory Filings and Compliance
AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
Neutral
Jun 1, 2026
AstraZeneca has confirmed that as of 31 May 2026 its issued share capital with voting rights stands at 1,551,009,750 ordinary shares, with no shares held in treasury. This figure establishes the total number of voting rights in the company and wil...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca Wins First U.S. Immunotherapy Combo Approval in Early Bladder Cancer
Positive
May 29, 2026
AstraZeneca has secured U.S. FDA approval for Imfinzi in combination with Bacillus Calmette-Guérin as the first immunotherapy regimen for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer, a setting with high re...
Product-Related AnnouncementsRegulatory Filings and Compliance
FDA Extends Decision Timeline on AstraZeneca’s Camizestrant Breast Cancer Filing
Negative
May 27, 2026
AstraZeneca said the U.S. FDA has extended the decision date for its camizestrant new drug application, which seeks approval of the oral SERD in combination with CDK4/6 inhibitors as a first-line treatment for HR-positive, HER2-negative advanced b...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
AstraZeneca Wins Landmark U.S. Approval for Datroway in Hard-to-Treat Breast Cancer
Positive
May 26, 2026
AstraZeneca and Daiichi Sankyo have secured U.S. approval for Datroway, a TROP2-directed antibody drug conjugate, as a first-line treatment for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
AstraZeneca’s Enhertu Wins Key EU Backing as First Tumour-Agnostic HER2 Therapy
Positive
May 26, 2026
AstraZeneca and Daiichi Sankyo’s HER2-directed antibody drug conjugate Enhertu has received a positive opinion from the European Medicines Agency’s CHMP as a monotherapy for adults with previously treated unresectable or metastatic HER...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
AstraZeneca Wins EU Backing for Camizestrant Combo in First-Line Advanced ER-Positive Breast Cancer
Positive
May 26, 2026
AstraZeneca has received a positive opinion from the EMA’s CHMP for camizestrant in combination with a CDK4/6 inhibitor as a first-line treatment for ER-positive, HER2-negative locally advanced or metastatic breast cancer in patients whose t...
Executive/Board ChangesRegulatory Filings and Compliance
AstraZeneca CEO Pascal Soriot Receives Vesting of Performance Share Award
Positive
May 18, 2026
AstraZeneca has disclosed that Chief Executive Officer Pascal Soriot received a vesting of 18,359 ordinary shares under the AstraZeneca Performance Share Plan, following a three-year performance period and a subsequent two-year holding period. The...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
FDA approvals extend Enhertu into curative-intent HER2-positive early breast cancer
Positive
May 18, 2026
AstraZeneca and Daiichi Sankyo have secured U.S. FDA approval for two new indications of Enhertu in HER2-positive early breast cancer, covering both neoadjuvant and adjuvant use based on Phase III DESTINY-Breast11 and DESTINY-Breast05 trials. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.